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ABSTRACT 
Burkholderia pseudomallei is a gram-negative soil bacterium and the causative agent of 
melioidosis, a disease of humans and animals. It is also listed as a category B bioterrorism threat 
agent by the US Center for Disease Control and Prevention, and there is currently no melioidosis 
vaccine available. Small modified nucleotides such as the hyper-phosphorylated guanosine 
molecules ppGpp and pppGpp play an important role as signaling molecules in prokaryotes. 
They mediate a global stress response during starvation conditions and have been implicated in 
the regulation of virulence and survival factors in many bacterial species. In this study, we have 
created a relA spoT double mutant in B. pseudomallei strain K96243, which lacks (p)ppGpp-
synthesizing enzymes, and investigated its phenotype in vitro and in vivo. The B. pseudomallei 
∆relA∆spoT mutant displayed a defect in stationary phase survival and intracellular replication 
in murine macrophages. Moreover, the mutant was attenuated in the Galleria mellonella insect 
model and in both acute and chronic mouse models of melioidosis. Vaccination of mice with the 
∆relA∆spoT mutant resulted in partial protection against infection with wild type B. 
pseudomallei. In summary, (p)ppGpp signaling appears to represent an essential component of 
the regulatory network governing virulence gene expression and stress adaptation in B. 
pseudomallei and the ∆relA∆spoT mutant may be a promising live-attenuated vaccine candidate. 
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INTRODUCTION 
Burkholderia pseudomallei, a Gram-negative, motile, aerobic bacterium of the class β-
proteobacteria, is widely distributed throughout the biosphere and is the causative agent of the 
life threatening disease melioidosis (7). Infection with B. pseudomallei presents with a variety of 
nonspecific symptoms and can range from acute disease, which is rapidly fatal, to chronic or 
latent (i.e. asymptomatic) infections that last for several decades (9). Despite antibiotic 
treatment, mortality rates for acute melioidosis can be 40- 50% in endemic areas, and relapse 
rates in surviving individuals are also high [for a review see Wiersinga et al. (48)]. Currently, 
there is no vaccine available and therefore, B. pseudomallei is listed as a category B select agent 
by the U.S. Center for Disease Control and Prevention. 
Guanosine tetra- and pentaphosphates, collectively referred to as ppGpp, are small signaling 
molecules that are produced in response to various stress conditions such as amino acid 
starvation [for reviews see Cashel et al. (6), Magnusson et al. (27), Potrykus & Cashel (39), and 
Dalebroux et al. (12)]. ppGpp signaling is widespread across various genera of the bacterial 
kingdom, but can also be found in plant chloroplasts (4). The ppGpp response has been 
extensively studied in Escherichia coli. In this organism, stress-induced ppGpp interacts with the 
RNA polymerase core enzyme and elicits a down-regulation of ribosomal proteins and DNA 
replication and an up-regulation of amino acid synthesis operons and genes involved in 
adaptation to stasis. This so-called “stringent response” mechanism causes the bacterial cell to 
stall growth and to redirect its resources to promote survival mechanisms until nutrient 
conditions improve. 
In many γ-proteobacteria, ppGpp is synthesized from GTP and ATP by two enzymes, RelA and 
SpoT (see Fig. 1B). The latter is a bifunctional enzyme that has both synthetase and hydrolase 
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activities. Deletion of the spoT gene is lethal due to toxic accumulation of ppGpp in the cell. On 
the other hand, deletion of both the relA and the spoT gene has a dramatic impact on gene 
expression profiles: microarray analyses of strains lacking ppGpp-synthesizing enzymes have 
revealed de-regulation of several hundreds of genes (18, 34, 46), thereby highlighting the role of 
ppGpp as a global signaling molecule. 
The diverse phenotypes of ppGpp-deficient strains indicate that this molecule affects various 
cellular processes, many of them involved in survival and adaptation to stress conditions, but 
also other cellular processes such as sporulation, competence, quorum sensing and virulence 
[reviewed by Magnusson et al. (27), Braeken et al. (5), and Dalebroux et al. (12)]. For example, 
in pathogenic bacteria such as Francisella tularensis, Brucella sp., Campylobacter jejuni, 
Legionella pneumophila, Helicobacter pylori, and Mycobacterium tuberculosis, absence of 
ppGpp-synthesizing enzymes results in defects in stationary phase survival, defects in 
intracellular replication and attenuation in animal models of disease (10, 11, 16, 17, 21, 24, 41, 
49). 
In addition to their greatly reduced virulence, strains defective in ppGpp synthesis have been 
shown to confer protective immunity against challenge with wild type bacteria. This is the case 
in Salmonella enterica serovar Typhimurium (33), Salmonella enterica serovar Gallinarum (37), 
Francisella tularensis (16) and Yersinia pestis (44). In Y. pestis, protection was conferred via a 
mixture of Th1 and Th2 immune responses, as measured by IgG1 and IgG2a levels (44). In S. 
Typhimurium, the ppGpp mutant elicited serum and mucosal antibody responses, measured by 
IgA and IgG titers, as well as cellular immune responses as measured by a Delayed Type 
Hypersensitivity (DTH) response (33). Similarly, in S. enterica, vaccination induced a B-cell 
response in blood measured by IgM, IgA and IgG levels, and induced CD4+ and CD8+ T-cell 
proliferation and IFN-γ and TGF-β4 cytokine production in spleens (37). This may render 
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ppGpp-deficient Salmonella strains a promising live-attenuated vaccine against typhoid in 
chicken. 
Here, we have evaluated a ∆relA ∆spoT double mutant in B. pseudomallei strain K96243 as a 
vaccine candidate. Live-attenuated vaccines offer the advantage of containing complex epitopes, 
thus stimulating both the antibody and cell-mediated arms of the immune system. This is of 
particular importance with facultative intracellular pathogens such as B. pseudomallei. 
Moreover, live-attenuated vaccines usually confer strong and longer lasting immunity. Several 
live-attenuated vaccine strains of B. pseudomallei have been tested to date [reviewed by Sarkar-
Tyson & Titball (42) and Patel et al. (38)]. Most of them represent mutants with defects in the 
intracellular life stages such as mutants in biosynthetic pathways or type III secretion systems. 
For example, the most successful B. pseudomallei vaccine strain characterized to date, strain 
2D2, carries a mutation in the ilvI gene, which renders the strain auxotrophic for the synthesis of 
branched chain amino acids (3). However, none of the live-attenuated vaccine candidates tested 
to date are able to confer sterilizing immunity or are able to protect against chronic disease (38). 
This demonstrates the need to assess whether different classes of mutants exhibit improved 
protective efficacy. 
Here, we have targeted an important signaling system, namely synthesis of the alarmone ppGpp, 
for mutagenesis in B. pseudomallei. We found that the ∆relA∆spoT derivative was severely 
attenuated in both acute and chronic models of disease and subsequently, we tested the ability of 
the mutant to confer protective immunity. Our results from protection studies in mice indicated 
that this mutant might be a medically relevant addition to the list of live-attenuated vaccines 
against melioidosis. 
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MATERIALS AND METHODS 
 
Bacterial strains and culture conditions. All strains and plasmids used in this study are listed 
in Table 1. Unless stated otherwise, bacteria were grown with aeration in Luria broth (LB) at 
37°C. When required, antibiotics chloramphenicol (Sigma-Aldrich, Gillingham, UK), 
kanamycin (Sigma-Aldrich) and gentamicin (Sigma-Aldrich) were used at concentrations of 
25 µg/ml, 50 µg/ml, and 50 µg/ml, respectively. 
Mutant construction. In-frame deletion mutants were constructed using a suicide plasmid 
containing regions homologous to up- and downstream regions of the target genes (26). 
Amplified DNA fragments used for constructing the suicide plasmid derivatives were generated 
by recombinant PCR. Briefly, 600 bp up- and downstream fragments of the relA (BPSL1946) 
and spoT (BPSL2561) genes of B. pseudomallei strain K96243 were PCR amplified using 
primer combinations relA-1&relA-2 (upstream), relA-3&relA-4 (downstream), spoT-1&spoT-2 
(upstream), and spoT-3&spoT-4 (downstream), respectively, and K96243 genomic DNA as a 
template. A second, recombinant PCR was performed using the outside primers (relA-1&relA-4 
and spoT-1&spoT-4) and the respective up- and downstream PCR fragments from the first PCR 
as a template. The resulting 1.2 kb recombinant PCR products designated ∆relA and ∆spoT were 
cloned into the suicide vector pDM4 via its XhoI/SphI and SalI/XmaI-sites, respectively. The 
presence of the recombinant PCR fragments in the resulting plasmids pDM4-∆relA and pDM4-
∆spoT was confirmed by PCR using primer combinations relA-up&relA-down and spoT-
up&spoT-down, respectively. All plasmids were maintained in E. coli DH5 λ pir cells. The 
sequences of all primers are listed in Table 2. 
 7 
Biparental mating. The pDM4-derivatives were introduced into E. coli strain S17 λ pir by 
electroporation. The resulting donor strains and the B. pseudomallei recipient strains were grown 
over-night in LB medium at 37°C with aeration. 1 ml of the cultures was pelleted by 
centrifugation and the cells were resuspended in 0.5 ml fresh LB medium. 10 μl of these 
suspensions were transferred onto 1 cm x 1 cm sized squares of nitrocellulose membrane 
(Hybond-ECL; GE Healthcare, Little Chalfont, UK) placed on brain heart infusion (BHI; 
Fluka_Sigma-Aldrich) agar plates, either singularly for the control plates or donor and recipient 
together for the conjugations, and the plates were incubated over-night at 37°C. The cells were 
scraped off the membranes using sterile inoculation loops and transferred to tubes containing 
1 ml sterile PBS. 100 μl of these suspensions were plated onto LB agar plates supplemented with 
gentamicin to select against the donor strain and chloramphenicol to select for B. pseudomallei 
transconjugants carrying the pDM4 constructs integrated into the chromosome. 
Allelic exchange. The generation of clean in-frame deletion mutants relied on a second 
recombination event, where the integrated pDM4 plasmid constructs were deleted from the 
chromosome by using sacB-mediated counter-selection. Overnight cultures sacB+ 
transconjugants were serially diluted in sterile PBS and plated onto salt-free LB agar plates 
containing 10% (w/v) sucrose, which were incubated at 24°C for 2-3 days. Colonies obtained on 
these plates were tested for sensitivity to chloramphenicol by patching them onto LB agar plates 
with and without chloramphenicol. Chloramphenicol-sensitive colonies were analyzed for 
carrying a deletion of the target gene. Confirmation of the mutants was performed by PCR using 
a primer that binds upstream of the fragment used for mutagenesis (primer series 3) combined 
with a reverse primer that binds within the coding region of the target gene (primer series 5), 
thus only resulting in a PCR product with wild-type cells, or a reverse primer that binds within 
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the downstream region used for mutagenesis (primer series 4), thus resulting in different sized 
fragments with wild-type and deletion mutants. Mutants were also confirmed by performing RT-
PCR using primer combinations relA-RT-1& relA-RT-2 and spoT-RT-1& spoT-RT-2, which 
specifically amplify the relA and spoT transcripts, respectively, as described below. 
The relA spoT double mutant was obtained by firstly deleting the relA gene, followed by a 
second round of mutagenesis deleting the spoT gene. A single spoT deletion mutant could not be 
obtained, despite several attempts. 
RNA extractions. For transcriptional studies, bacteria were grown aerobically at 37°C in LB 
broth overnight. Total RNA was extracted from 4.5 ml of these stationary phase cultures using 
Trizol reagent (Invitrogen, through Life Technologies, Paisley, UK) according to the 
manufacturer’s recommendations. In brief, cells were harvested by centrifugation at 12,000 rpm 
for 5 mins. Each cell pellet from 1.5 ml culture was resuspended in 1 ml Trizol reagent. Cells 
were lysed by pipetting and samples were stored at -80°C until they had passed a sterility check. 
Total RNA was extracted after adding chloroform and precipitated in isopropanol over-night at -
20°C . The RNA was pelleted by centrifugation, washed with 70% ethanol, air dried for 5 mins 
at room temperature and resuspended in nuclease-free water. Contaminating DNA was removed 
by DNase I (Ambion, through Life Technologies, Paisley, UK) digestion for 45 mins at 37°C, 
followed by phenol / chloroform extractions, isopropanol precipitation and re-suspension of the 
total RNA in nuclease-free water as described above. 
Semi-quantitative RT-PCR. For cDNA synthesis, 4 µg of total RNA was mixed with 3 µl of 
random primers at 3 μg/μl (Invitrogen) and 1 µl of a dNTP mixture at 10 mM each (Promega, 
Southampton, UK). After primer annealing at 65°C for 5 mins, a mix of first-strand buffer, DTT, 
40 U RNase OUT recombinant RNase inhibitor (Invitrogen), and 200 U Superscript III reverse 
transcriptase (Invitrogen) was added according to the manufacturer's recommendations. cDNA 
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synthesis was performed at 50°C for 60 mins, followed by heat inactivation at 70°C for 15 mins. 
cDNA samples were 10x diluted in water and directly used for PCR amplification. For the 
adjustment of cDNA amounts, 16S rRNA was used as an internal standard, using primers 16S-
RT-1 & 16S-RT-2. The sequences of all primers are listed in Table 2. 
Macrophage uptake and intracellular survival assays. Bacterial uptake and survival inside 
macrophages were quantified using a modified kanamycin protection assay as described (47). In 
summary, J774A.1 murine macrophages were infected at an MOI of 10 and incubated at 37°C 
for 2 hrs to allow bacterial internalization to occur. The medium was then replaced with fresh 
medium containing 250 µg/ml kanamycin in order to suppress growth of extracellular bacteria. 
At appropriate time points, cells were washed, lysed in 0.1% (v/v) Triton X-100 and serial 
dilution of the lysis mixture were plated out on LB agar plates for the determination of 
intracellular bacterial numbers. 
Galleria mellonella killing assays. Bacterial survival and virulence towards G. mellonella 
larvae was assessed by killing assays as described (47). Briefly, 1x104 CFU of bacteria in a 
volume of 10 μl were injected into the hemocoel of 10 larvae per bacterial strain. Larvae were 
incubated statically at 37°C inside petri dishes and the number of dead larvae was scored 
periodically. Intracellular bacterial numbers were determined 20 hrs post infection by draining 
the hemocoel of three larvae per strain and plating out serial dilutions onto LB agar plates. 
Animal infection studies. Female C57BL/6 mice (6-8 week-old; Harlan Laboratories, Bicester, 
Oxon, UK) were used throughout the studies. All animal experiments were performed in 
accordance with the guidelines of the Animals (Scientific Procedures) Act of 1986 and were 
approved by the local ethical review committee at the London School of Hygiene and Tropical 
Medicine. For each infection, aliquots were thawed from frozen bacteria stocks and diluted in 
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pyrogen-free saline (PFS). Prior to intranasal infection, mice were anesthetized intraperitoneally 
with ketamine (50 mg/kg; Ketaset; Fort Dodge Animal, Iowa, USA) and xylazine (10 mg/kg; 
Rompum; Bayer, Leverkusen, Germany) diluted in PFS. Infection was performed administering 
a total volume of 50 µl i.n. containing 2,500 colony forming units (CFU; acute model) or 100 
CFU (chronic model) of B. pseudomallei K96243 wild type or isogenic ∆relA∆spoT mutant. 
Infection dose was confirmed as described elsewhere (22). Control uninfected mice received 50 
µl i.n. of PFS. 
Immunisation studies. Female C57BL/6 mice were immunized i.n. with 1x105 CFU of B. 
pseudomallei 2D2 (3) or the ∆relA∆spoT mutant in a volume of 50 µl. Sham immunized mice 
received 50 µl PFS. Five weeks later they were challenged i.n. with 1x103 CFU of B. 
pseudomallei strain 576 in a volume of 50 µl and survival was monitored. On day 55 post 
infection, survivors were culled and lungs and spleens aseptically removed into cold PBS. 
Organs were homogenized through a 100 µm cell strainer (BD Falcon, California, USA), serial 
10-fold dilutions of tissue homogenates were plated onto tryptic soy agar plates (Sigma-
Aldrich), and bacterial colonies were counted after incubation for 24-48 hours at 37oC. The 
limits of detection were 50 CFU/organ. 
Bright field microscopy. 10 µl of bacterial cultures were applied onto cover slips placed inside 
the wells of a 24-well plate and cells were fixed using paraformaldehyde (4% in PBS) for 30 
mins. The cover slips were washed three times in phosphate-buffered saline and inverted onto a 
drop of Vectashield mounting medium (Vector Laboratories) on top of a glass slide. The 
microscope slide were fumigated over night before they could be removed from the BSL3 suite. 
Samples were imaged at 100x magnification using a Zeiss Axiophot microscope equipped with 
VisiView software (Visitron Systems GmbH). 
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In silico analyses. Homologies between amino acid sequences were determined using NCBI’s 
BLASTP algorithm. Conserved domains were analyzed using NCBI’s conserved domain 
database (CDD). Promoter predictions were performed using the Bprom software 
(www.softberry.com). 
Statistical analyses. Differences between average values were tested for significance by 
performing an unpaired, two-sided Student’s t-test. Log-Rank tests of survival data were 
performed using the GraphPad Prism software version 5.01 (GraphPad Software, San Diego 
California USA). p values of ≤ 0.05 were considered significant. 
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RESULTS 
RelA and SpoT proteins in B. pseudomallei. 
RelA and SpoT play key roles in the generation of ppGpp in bacteria. The genome of B. 
pseudomallei strain K96243 was searched for homologues of the RelA and SpoT proteins of 
Escherichia coli, which produced two matches. BPSL1946 (predicted MW = 82.3 kDa) had 40% 
overall identity to RelAE.coli, whereas BPSL2561 (predicted MW = 88 kDa) had 45% identity to 
SpoTE.coli. Interestingly, no significant similarity was detected in the first 40 amino acid residues 
of the N-terminus of RelABps, whereas the start codon of SpoTBps seemed to be miss-annotated by 
59 amino acid residues. The identity between the two paralogs was 34%, and both proteins were 
conserved in the closely related species B. mallei and B. thailandensis. The B. pseudomallei 
proteins possess typical conserved domains for RelA-SpoT-family proteins (28). No other RelA 
SpoT family proteins were found in the genome by BLAST and PFAM searches. The 
organization of the chromosomal regions surrounding the relA and spoT genes, respectively, is 
depicted in Fig. 1A. 
To further characterize the two proteins and the contribution of ppGpp synthesis in B. 
pseudomallei, a ∆relA single mutant and a ∆relA∆spoT double mutant were created in B. 
pseudomallei strain K96243. The correct genotypes of the mutants were confirmed by PCR, and 
the absence of relA and / or spoT transcripts was confirmed by reverse-transcription PCR (data 
not shown). Since both genes are located at the end of putative transcriptional units, no polar 
effects on downstream genes is expected (see Fig. 1A). A ∆spoT single mutant could not be 
obtained despite several attempts. 
 
Stationary phase survival is decreased in a ∆relA∆spoT double mutant of B. pseudomallei. 
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As a first phenotypic test, the growth of the mutants in axenic culture was analyzed. Both the 
∆relA single mutant and a ∆relA∆spoT double mutant grew at similar rates as the wild type 
during exponential growth in LB medium (Fig. 2A). Cultures of the ∆relA∆spoT mutant reached 
higher optical densities than cultures of the wild type and the ∆relA single mutant at the 
transition into stationary phase between 12 and 24 hrs post inoculation, but the optical density 
decreased steadily during the remainder of the experiment. The optical densities of wild type and 
∆relA mutant cultures remained at a constant level throughout stationary growth phase and were 
found to be 2-times higher than the values observed with the ∆relA∆spoT mutant on day 13. 
Despite the elevated optical density after 24 hrs incubation, the number of colony forming units 
(CFU) in cultures of the ∆relA∆spoT mutant was lower than in cultures of the wild type and the 
∆relA single mutant (Fig. 2B), and numbers further decreased over time until no viable bacteria 
could be detected at day three after inoculation (Fig. 2B). In contrast, the number of viable cells 
remained constant in cultures of the wild type for up to one week post inoculation, and only 
decreased marginally during the second week. The survival of the ∆relA single mutant was more 
variable, with two out of four cultures exhibiting a decrease in the number of CFUs over time. 
However, on average, there was no significant difference to the wild type (Fig. 2B). This 
indicates a severe defect in stationary phase survival only in the absence of both ppGpp-
synthesizing enzymes, similar to what has been described in other organisms (21, 31, 41). 
In keeping with this finding, early stationary growth phase cells of the ∆relA single mutant did 
not appear to differ in size and shape from wild type cells (Fig. 1C&D). In contrast, cells of the 
∆relA∆spoT mutant appeared slightly bigger on average (Fig. 1E, left panel), or had formed 
filaments of various lengths (Fig. 1E, right panel), thereby indicating stress-related changes in 
cell morphology in the absence of both ppGpp-synthesizing enzymes. 
 14 
 
A ∆relA∆spoT mutant of B. pseudomallei is unable to replicate inside macrophages. 
B. pseudomallei is a facultative intracellular organism that can survive inside macrophages. In 
order to assess the intracellular survival ability of the ∆relA and ∆relA∆spoT mutants, murine 
macrophages were infected with B. pseudomallei K96243 or isogenic mutants and the numbers 
of intracellular bacteria were determined up to 10 hrs post infection. While the wild type 
exhibited intracellular replication over the course of the experiment, the numbers of the 
∆relA∆spoT mutant did not increase compared to the input (p = 0.024 at 10 hrs p.i.; see Fig. 3). 
The extent of bacterial uptake into phagocytic cells, represented by the number of bacteria at 2 
hrs post initial infection, was not altered between the mutant and the wild type. The ∆relA single 
mutant exhibited an intermediate replication rate and no significant difference in initial bacterial 
numbers. This suggests that the presence of RelA/SpoT family proteins is crucial for 
intracellular survival in phagocytic cells. 
 
A ∆relA∆spoT mutant of B. pseudomallei is attenuated in an insect model of infection. 
Previously, we have demonstrated the value of wax moth (G. mellonella) larvae as a model 
system to assess virulence of B. pseudomallei isolates (47). Here, G. mellonella larvae were 
infected with 1x104 CFU of B. pseudomallei K96243 or isogenic mutants and survival of the 
larvae was monitored (Fig. 4A). The median survival of larvae infected with the wild type was 
24 hrs, whereas infection with the ∆relA mutant resulted in a median survival of 30 hrs (Log-
rank test p = 0.004). No larvae infected with the ∆relA∆spoT double mutant had died by the end 
of 35 hrs (p = 0.002). When enumerating bacteria inside the larvae prior to the onset of paralysis 
at 20 hrs post infection, a >2,000-fold increase in bacterial numbers compared to the input was 
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observed with the wild type (Fig. 4B). The growth of the ∆relA and ∆relA∆spoT mutants was 2-
times and 11-times lower compared to wild type, respectively. This indicates a severe 
intracellular growth defect and a significant attenuation in insect virulence in the absence of 
RelA/SpoT family proteins. 
 
K96243 ∆relA∆spoT is attenuated in murine models of infection and is able to induce a 
protective immune response. 
To further investigate the role of RelA and SpoT in virulence, C57BL/6 mice were infected i.n. 
with B. pseudomallei K96243 or the ∆relA∆spoT double mutant at two different doses. A high 
dose of 2,500 CFU of B. pseudomallei K96243 has been shown to result in acute disease with 
death of the mice occurring within 10 days post infection, whereas a lower dose of <1,000 CFU 
results in a chronic infection (8). The ∆relA∆spoT double mutant was attenuated in both the 
acute and the chronic model of infection and all mice survived for at least up to 70 days post 
infection (Fig. 5A&B). None of the mice infected with the B. pseudomallei ∆relA∆spoT mutant 
exhibited any outward signs of disease or weight loss. 
To test whether the ∆relA∆spoT mutant is able to protect mice from subsequent infection, 
C57BL/6 mice were immunized i.n. with 1x105 CFU of K96243 ∆relA∆spoT or B. pseudomallei 
strain 2D2 as a positive control and challenged 5 weeks later with 1x103 CFU of B. pseudomallei 
strain 576 given i.n., which usually results in an acute infection in naïve mice with a time to 
death of <10 days post infection. Immunization of mice with K96243 ∆relA∆spoT resulted in 
significantly increased survival of mice compared to PFS control mice with 100% survivors up 
to 30 days post challenge (p = 0.0061; Fig. 5C). The pattern of survival of the immunized 
animals was comparable to the pattern of survival of mice that had been immunized with strain 
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2D2. Colonization data of lungs and spleens of surviving animals that had been vaccinated with 
the K96243 ∆relA∆spoT mutant resulted in undetectable CFU levels in three out of five mice at 
day 55 p.i. with the wild type (Fig. 5D&E). However, bacteria could be detected in the 
remaining mice and one spleen sample exhibited extremely large abscesses. This indicates that 
vaccination with a ∆relA∆spoT mutant of B. pseudomallei induces high levels of protective 
immunity against B. pseudomallei infection but, as with all other live-attenuated vaccines tested 




In this study we have characterized the phenotype of a ∆relA∆spoT derivative of B. 
pseudomallei and have assessed its potential to confer protective immunity on mice. Our results 
demonstrate that RelA/SpoT family proteins play an important role in survival and virulence of 
B. pseudomallei and that a ∆relA∆spoT mutant may be a promising live-attenuated vaccine 
candidate. 
The ppGpp-mediated stringent response is not well characterized in members of the β-
proteobacteria. In phylogenetic analyses, it has been shown that RelA and SpoT proteins of β-
proteobacteria such as Bordetella sp. and Neisseria sp. cluster next to the γ-proteobacterial 
branch (30). ppGpp production has been described in Neisseria gonorrhoeae (20). In contrast to 
E. coli, the gonococcal SpoT protein does not seem to contribute to ppGpp production and a relA 
single mutant had a growth defect on rich solid medium. The B. pseudomallei proteins share 
45% and 44% identity with the RelA and SpoT proteins of N. gonorrhoeae, respectively. 
From our data, we propose that the stringent response in B. pseudomallei may be similar to the 
one observed in E. coli. Firstly, we were unable to create a spoT single mutant, which indicates 
that SpoT is the only enzyme that can hydrolyze ppGpp in B. pseudomallei and thus prevent 
toxic accumulation. Moreover, the intermediate phenotype of the relA single mutant and its 
normal growth rate indicate that SpoTBps also contributes to ppGpp synthesis. Interestingly, as 
seen in Fig. 1A, SpoTBps is encoded upstream of the transcription elongation factor GreB, which 
also interacts with the RNA-polymerase through the secondary channel (25), similarly to ppGpp 
but with different effects (1, 40). More detailed studies on the stringent response in B. 
pseudomallei could provide a better understanding of survival and adaptability capacities of this 
organism. 
 18 
Here, we characterized the phenotype of a B. pseudomallei mutant that is defective in 
RelA/SpoT enzymes usually involved in ppGpp synthesis and degradation. In other bacteria, it 
has been shown that lack of ppGpp-synthesizing enzymes results in defects in stationary phase 
survival (21, 31, 41). Our results show that this is also the case in B. pseudomallei. The 
∆relA∆spoT mutant had lost all viability after three days incubation (Fig. 2B). The viability of 
the ∆relA single mutant seemed to be variable, with some cultures having lost viability after one 
week, some exhibiting an initial decrease in CFU followed by a plateau at intermediate levels, 
and others showing no difference to the wild type (data not shown), which might indicate the 
involvement of suppressor mutants or other stochastic effects, which remain to be elucidated. 
The assumed role of the ppGpp-mediated stringent response is to reduce growth when cells 
encounter unfavorable growth conditions, including nutrient deprivation upon entry into 
stationary phase, and to redirect resources into adaptation and survival mechanisms (27). In 
general, ppGpp mutants seem to be unable to modulate their growth rates and prepare for 
stationary phase survival. Stationary phase adaptation includes morphological changes such as a 
reduced cell size and rounding of cells (36). The morphology of ∆relA∆spoT mutant cells 
differed from wild type cells as the mutant cells appeared slightly bigger on average (compare 
Fig. 1C and E). This suggests that the ∆relA∆spoT mutant is unable to adopt a different 
morphology in response to stationary phase growth, whereas the filamentation indicates that the 
bacteria experience stress, and we speculate that these two effects might contribute to the 
reduced survival. 
In this study, we have assessed the virulence of the relA spoT mutants in three different infection 
models: a macrophage in vitro model, an insect model, and mouse models of acute and chronic 
melioidosis. The ∆relA∆spoT double mutant was found to be severely attenuated in all of the 
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models, whereas the ∆relA single mutant exhibited intermediate levels of attenuation in the two 
model systems tested. Previously, we have demonstrated the usefulness of the macrophage 
model and the Galleria mellonella insect model for comparing the virulence of different 
Burkholderia isolates (47). Our results presented here demonstrate that either model can also be 
used to assess the virulence of mutants, and in our case, the virulence in the non-mammalian 
models reflected the virulence in mice. Both model systems also provided further insights into 
the possible mode of attenuation: mutants lacking ppGpp-synthesizing enzymes are not 
attenuated due to reduced bacterial uptake or due to enhanced killing and clearance by 
macrophages and insect hemocytes, but rather due to a defect in intracellular replication (see 
bacterial numbers in Fig. 3 and Fig. 4B). The macrophage model may also prove useful to 
elucidate the role of ppGpp in the intracellular lifestyle of B. pseudomallei in future studies. 
In addition to being severely attenuated in mice, both in an acute and a chronic model of disease, 
the K96243 ∆relA∆spoT double mutant also partially protected immunized animals from 
intranasal challenge with virulent wild type bacteria (Fig. 5C). Pioneering studies of Dannenberg 
and colleagues (13-15) already demonstrated the feasibility of immunization against 
experimental melioidosis using attenuated B. pseudomallei. However, the genetic basis of 
attenuation of these strains is not known. More recently, other workers have assessed the 
feasibility of immunization against experimental melioidosis using rationally attenuated B. 
pseudomallei mutants. Immunization by the i.p. route, with a range of mutants, has been shown 
to protect against acute disease following a subsequent i.p. challenge with wild type B. 
pseudomallei (35, 42). However, disease following an i.n. or inhalational challenge is more 
severe than that seen following i.p. challenge (45) and there are few studies which have 
demonstrated protection against an i.n. or inhalational challenge. In part, this might reflect the 
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finding that protection against an i.n. challenge appears to be dependent on immunization by the 
same route (19). Immunization of BALB/c mice i.n. with two doses of an Δasd mutant has been 
shown to provide protection against acute disease following a low dose challenge (4 LD50 
doses), but deaths of challenged mice were recorded from day 15 post challenge onwards (35). A 
similar pattern of protection was observed after i.n. immunization of BALB/c mice with an ilvI 
mutant (2D2), after i.n. challenge with 1x102 CFU of wild type B. pseudomallei (19). However, 
these studies have been carried out in BALB/c mice and we have recently reported that the 
C57BL/6 infection model reflects the spectrum of melioidosis seen in humans (8). Therefore, we 
considered that the C57BL/6 infection model would allow a more meaningful assessment of the 
potential for live-attenuated mutants to induce protective immunity in humans. In this study, we 
report that C57BL/6 mice immunized i.n. with either 2D2 or the ∆relA∆spoT mutant of B. 
pseudomallei were protected against acute disease following an i.n. challenge (1x103 CFU) of B. 
pseudomallei strain 576, which has proven to provide a robust measure of protection in many 
other vaccination studies. However, like previous studies, mice eventually succumbed to disease. 
In addition to incomplete protection by B. pseudomallei live-attenuated vaccines, concerns exist 
over their safety. The vaccine strain, even though unable to cause overt disease, might persist in 
the host and cause disease later in life. All our data indicate a defect of the B. pseudomallei 
∆relA∆spoT mutant in long-term survival in broth culture and in macrophages, but the strain has 
not been tested for latency in vivo. Moreover, suppressor mutations of ppGpp-deficient strains 
have been reported in E. coli, which abolish their auxotrophy on minimal media plates (6, 32, 
50). Therefore, more studies on the liability to acquire suppressor mutations and on the 
molecular mechanism of the intracellular replication defect, including subcellular localization 
experiments, have to be performed on the B. pseudomallei ∆relA∆spoT mutant before it can be 
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considered safe. Nevertheless, identification of different classes of protective vaccine strains 
may be useful for the creation of a live-attenuated vaccine strain carrying a combination of 
mutations, which could increase both protection and safety. 
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Table 1 – Strains and plasmids used in this study. 
 Description Reference 
Strains   
B. pseudomallei K96243 Clinical isolate from Thailand (23) 
B. pseudomallei K96243 
∆relA 
Inactivation of BPSL1946 (relA) by complete deletion This study 
B. pseudomallei K96243 
∆relA∆spoT 
Inactivation of BPSL1946 (relA) and BPSL2561 (spoT) by 
complete deletion 
This study 
B. pseudomallei 576 Clinical isolate from Thailand (2) 
B. pseudomallei 2D2 Auxotroph transposon mutant of B. pseudomallei 576 (3) 
E. coli DH5 λ pir recA1 gyrA (Nal) Δ(lacIZYA-argF) (φ80dlacΔ [lacZ]M15) 
pirRK6 
(43) 
E. coli S17-1 λ pir RPA-2 tra regulon, pirRK6, SmR, TpR (43) 
Plasmids   
pDM4 Suicide vector with R6K origin; CmR (29) 
pDM4-∆relA 600 bp up-and downstream of relA cloned into pDM4 via 
XhoI/SphI sites 
This study 






Table 2 – Oligonucleotides used in this study. Restriction sites are underlined. Complementary 
region are indicated in italics. Translational start and stop codons are highlighted in bold. 
Name Sequence (5’ – 3’) Purpose 
relA-1-fw CCCCTCGAGGAAGGCGCGCGGACAAGCGG Mutagenesis 
relA-2-rv CGGCGCTCACTGCAGCATCGTCGGGTATGGCCAGTT Mutagenesis 
relA-3-fw CCGACGATGCTGCAGTGAGCGCCGCCGGTGGGCCGC Mutagenesis 
relA-4-rv CCCGCATGCCGTATCGACGAGTTCGCCGTC Mutagenesis 
spoT-1-fw GCGGTCGACCTGCCGCCGTCGCTCGCGGC Mutagenesis 
spoT-2-rv GCGGCGCTAACTAGTCATTTTCGCCTCCTGGGTTCG Mutagenesis 
spoT-3-fw GCGAAAATGACTAGTTAGCGCCGCGCGGCGCCCGAC Mutagenesis 
spoT-4-rv GCGCCCGGGGCCTGCGCGAAATCGAGGTCG Mutagenesis 
relA-up-fw ACAACGGCACCGTCTATCTC Confirmation of plasmids 
relA-down-rv GCGGTGTCATAACCGTATTC Confirmation of plasmids 
spoT-up-fw CTCGCATTACCGTTGAAGAC Confirmation of plasmids 
spoT-down-rv GCCCTTTCAGTTCGAAGTTG Confirmation of plasmids 
relA-3-fw GCGTGCAGTCGGACCTGCTG Confirmation of mutation 
relA-4-rv GTTCGGGAAAATTCGCAAGCC Confirmation of mutation 
relA-5-wt GTGGAAGCGGAATCGGCTG Confirmation of mutation 
spoT-3-fw GGTGAAGAAGCAGTTCCGCA Confirmation of mutation 
spoT-4-rv CGCCCGAAACAAATGGCGG Confirmation of mutation 
spoT-5-wt GCGGACGATGGTGTAGTGC Confirmation of mutation 
relA-RT-1 AGATCCGCACGCAGGAAATG RT-PCR analysis 
relA-RT-2 TTCGCTGTGCAGGTGGTAAG RT-PCR analysis 
spoT-RT-1 GCGCATCAATGGCTCAAGTC RT-PCR analysis 
spoT-RT-2 TTCAGGCGCATCGTCTTCAG RT-PCR analysis 
16S-RT-1 GCCAGTCACCAATGCAGTTC RT-PCR normalization 







Fig. 1: Genetic organization and enzymatic activities of RelA-SpoT family proteins in B. pseudomallei and 
cell morphology of RelA-SpoT family mutants. A) Schematic overview of the chromosomal regions surrounding 
the relA gene (BPSL1946; upper panel) and the spoT gene (BPSL2561; lower panel). Predicted promoters and their 
linear discriminant function (LDF) score are indicated in the figure. B) Schematic of the classical synthesis pathway 
of (p)ppGpp. pppGpp is produced from GTP and ATP by either RelA- or SpoT-dependent mechanisms and is 
subsequently converted to ppGpp. ppGpp interacts directly with the RNA polymerase enzyme (RNAP) and thus 
affects gene expression. The effects of ppGpp induction are relieved by SpoT-mediated hydrolysis of ppGpp. C-E) 
Cell morphology of B. pseudomallei strain K96243 wild type (C), a K96243 ∆relA single mutant (D), and a K96243 
∆relA∆spoT double mutant (E). All strains were grown to early stationary growth phase (24 hrs incubation at 37°C) 
in LB broth and bacterial cells were visualized by bright field microscopy at 100x magnification. The scale bars 
represent the average length of K96243 wild type cells. Two images of K96243 ∆relA∆spoT mutant cells are 





Fig. 2: Growth and stationary phase survival of K96243 wild type and isogenic mutants. All strains were 
inoculated into LB broth at an optical density of 0.01 and cultures were incubated at 37°C with aeration. A) Growth 
curve representing the optical densities of the cultures at indicated time points. B) Stationary phase survival of the 
strains determined by plating out samples onto LB agar plates at indicated time points. All experiments were 
performed in at least three independent experiments and data are plotted on a logarithmic scale as means with 





Fig. 3: Intracellular survival of K96243 wild type and isogenic mutants. J774A.1 murine macrophages were 
infected with K96243 wild type and isogenic mutants at an MOI of 10 and intracellular bacterial numbers were 
enumerated at indicated time points after initial infection by plating onto LB agar plates. Bars and error bars 
represent the means and standard deviation of a representative experiment performed in three technical replicates for 





Fig. 4. Killing of G. mellonella larvae by K96243 wild type and isogenic mutants. A) Groups of ten larvae per 
strain were injected with 1x104 CFU of bacteria and maintained at 37°C. Dead and live larvae were scored at 
indicated time points and plotted as Kaplan-Meier survival curves. All curves were significantly different from each 
other (Log-rank test; p < 0.01 in all cases). B) The number of bacteria present inside the larvae at 20 hrs post 
infection was determined by aseptically removing the bottom 2 mm of five larvae per strain, draining the hemocoel 





Fig. 5. Survival and protection of mice infected with K96243 wild type and isogenic ∆relA∆spoT mutant. A-
B) C57BL/6 mice were challenged intranasally with an intended dose of 2,500 CFU (acute challenge; panel A) or 
500 CFU (chronic challenge; panel B). Actual infection doses for each experiment are given in brackets in the figure. 
Log-rank tests confirmed a significant difference in survival between the wild type and the ∆relA∆spoT mutant in 
both cases (p < 0.001 and p < 0.05, respectively). C-E) C57BL/6 mice were immunized intranasally with 1x105 CFU 
of strains 2D2 or K96243 ∆relA∆spoT. After 5 weeks incubation, mice were challenged intranasally with 1,000 CFU 
of B. pseudomallei strain 576. Mice were monitored for survival and numbers are plotted as Kaplan-Meier survival 
curves (panel C). Log-rank tests confirmed a significant difference in survival between the K96243 ∆relA∆spoT and 
the 2D2 cohorts compared to the saline control (p < 0.01 and p < 0.05, respectively). At day 55 post infection with 
the wild type, bacterial burdens were assessed in lungs (panel D) and spleens (panel E) of survivors. Note: Only one 
mouse had survived up to this time point in the saline-treated sample group. The spleen of this mouse and one 
survivor of the K96243 ∆relA∆spoT sample group had extremely large abscesses and could not be harvested. N.A. = 
not available. 
